Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +13.05%
#3 Meteora Meteora +11.55%
#4 Bitway Bitway +10.13%
#5 Glidr Glidr +9.59%
#6 Unit Pump Unit Pump +8.98%
#7 Pump.fun Pump.fun +8.98%
#8 OPENLOOT OPENLOOT +8.59%
#9 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.72%
#10 eCash eCash +7.02%
Coin of the day
PulseChain PulseChain
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Rang in Aktien #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Aktienkurs
$0.55
Zuletzt synchronisiert: 2025-02-11
Marktkapitalisierung
$28.90M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Marinus Pharmaceuticals, Inc. (MRNS)

Kategorie

Healthcare
Operative Marge für Marinus Pharmaceuticals, Inc. (MRNS)
Operative Marge zum August 2026 TTM: -424.30%
Laut den neuesten Finanzberichten und dem Aktienkurs von Marinus Pharmaceuticals, Inc. beträgt die aktuelle operative Marge (TTM) -424.30%. Am Ende des Jahres 2022 lag die operative Marge bei -442.69%.
Historie der operativen Marge von Marinus Pharmaceuticals, Inc. von 2012 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -424.30% 0.00%
2023 -424.30% -4.15%
2022 -442.69% -29.92%
2021 -631.68% -84.03%
2020 -3,954.42% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% -100.00%
2012 -1,430.66% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.09%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -99.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.07%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.06%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.